Innovative use of dapsone

Dermatologic Clinics

Volumn 28, Issue 3, 2010, Pages 599-610

  Wozel, V E Gottfried ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Dapsone; Dermatology; Sulfone.

Indexed keywords

ACZONE; DAPSONE; PLACEBO; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACRODERMATITIS CONTINUA; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; AGRANULOCYTOSIS; AIDS RELATED COMPLEX; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMINURIA; ALOPECIA; ALOPECIA AREATA; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; APLASTIC ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATRIOVENTRICULAR BLOCK; BEHCET DISEASE; BILIRUBIN BLOOD LEVEL; BLINDNESS; BLOOD TOXICITY; BULLOUS DERMATITIS; BULLOUS PEMPHIGOID; CHOLESTATIC HEPATITIS; CHRONIC INFLAMMATION; CLINICAL PRACTICE; CLINICAL TRIAL; DERMATITIS HERPETIFORMIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROLYTE DISTURBANCE; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; EXFOLIATIVE DERMATITIS; GASTROINTESTINAL TOXICITY; GRANULOMA ANNULARE; HEPATITIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; INSOMNIA; JAUNDICE; KAPOSI SARCOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LICHEN PLANUS; LIVER INJURY; LONG TERM CARE; LUPUS MILIARIS DISSEMINATUS FACIEI; LYMPHOCYTIC INFILTRATION; LYMPHOMATOID PAPULOSIS; METHEMOGLOBINEMIA; MUSCLE WEAKNESS; MYCETOMA; NEPHROTOXICITY; NEUROTOXICITY; NOCARDIOSIS; PAUCIBACILLARY LEPROSY; PEMPHIGOID GESTATIONIS; PEMPHIGUS; PEMPHIGUS BENIGNUS CHRONICUS FAMILIARIS; PEMPHIGUS VULGARIS; PITYRIASIS ROSEA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PSYCHOSIS; RADIATION PROTECTION; RASH; REVIEW; ROSACEA; SIDE EFFECT; SKIN DISEASE; SKIN GRANULOMA; SKIN TOXICITY; TOXOPLASMOSIS; TRANSIENT ACANTHOLYTIC DERMATOSIS; ULTRAVIOLET RADIATION; URTICARIA; WELLS SYNDROME;

ADULT; ANTI-INFECTIVE AGENTS; AUTOIMMUNE DISEASES; CHILD; DAPSONE; HUMANS; HYPERSENSITIVITY; JAUNDICE; LEPROSY; ORPHAN DRUG PRODUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; SKIN DISEASES; THERAPIES, INVESTIGATIONAL; TOXOPLASMOSIS;

EID: 77953243832     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.03.014     Document Type: Review

References (69)

1. Doull J.A. Sulfone therapy of leprosy. Background, early history and present status. Int J Lepr 1963, 31:143-160.
2. Fromm E., Wittmann J. Derivate des p-nitrophenols. Berichte Deutsch Chem Ges 1908, 41:2264-2273.
3. Buttle G.A.H., Stephenson D., Smith S., et al. The treatment of streptococcal infections in mice with 4:4'diaminodiphenylsulfone. Lancet 1937, 1:1331-1334.
4. Fourneau E., Trèfouel J., Nitti F., et al. Action anti-streptococcique des derives sulfures organiques. C R Acad Sci 1937, 204:1763-1766.
5. Boyer H., Nitti F., Tréfouel J. Note preliminaire sur l' action de la paradiacetyl-aminodiphenyl sulfone (1399F) dans la blennorrhagic. Bull Soc Fr Dermatol Syphiligr 1889, 1937:44.
6. Palazzoli M., Bovet D. Action de la di(paracetylaminophenyl)sulfone (1399F) dans les urétrites gonococciques aiguës et chroniques. Bull Soc Fr Dermatol Syphiligr 1900, 1937:44.
7. Faget G.H., Pogge R.C., Johansen F.A., et al. The promin treatment of leprosy. Public Health Rep 1943, 58:1729-1741.
8. Esteves J., Brandão F.N. Acerca da açcão das sulfamidas e das sulfonas na doença de Duhring. Trab Soc Portuguesa Dermatol Venereol 1950, 8:209-217.
9. Sneddon I.B., Wilkinson D.S. Subcorneal pustular dermatosis. Br J Dermatol 1956, 68:385-394.
10. Dapson-Pharmakologie, Wirkmechanismus und klinischer Einsatz 1996, Georg Thieme Verlag, Stuttgart (Germany), New York. G. Wozel (Ed.).
11. Ahmad R.A., Rogers H.J. Pharmacokinetics and protein-binding of dapsone and pyrimethamine. Br J Clin Pharmacol 1980, 10:519-524.
12. Zuidema J., Hilbers-Modderman E.S.M., Merkus F.W.H.M. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986, 11:299-315.
13. AHFS drug information 2009, 605-609. American Society of Health-System Pharmacists, Bethesda (MD). G.K. Mc Evoy (Ed.).
14. Uetrecht J., Zahid N., Shear N.H., et al. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther 1988, 245:274-279.
15. Branski D., Kerem E., Gross-Kieselstein E., et al. Bloody diarrhea-a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastroenterol Nutr 1986, 5:316-317.
16. Sanders S.W., Zone J.J., Foltz R.L., et al. Hemolytic anemia induced by dapsone transmitted through breast milk. Ann Intern Med 1982, 96:465-466.
17. Wolf R., Tüzün B., Tüzün Y. Dapsone: unapproved uses or indications. Clin Dermatol 2000, 18:37-53.
18. Zhu Y.I., Stiller M.J. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001, 45:420-434.
19. Wozel G., Barth J. Current aspects of modes of action of dapsone. Int J Dermatol 1988, 27:547-552.
20. Niwa Y., Sakane T., Miyachi Y. Dissociation of the inhibitory effect of dapsone on the generation of oxygen intermediate-in comparison with that of colchicine and various scavengers. Biochem Pharmacol 1984, 33:2344-2360.
21. Stendahl O., Molin L., Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone. J Clin Invest 1978, 62:214-240.
22. Niwa Y., Sakane T., Shingu M., et al. Neutrophil-generated active oxygens in linear IgA bullous dermatosis. Arch Dermatol 1985, 121:73-78.
23. Miyachi Y., Niwa Y. Effects of potassium iodide, colchicine and dapsone on the generation of polymorphonuclear leukocyte-derived oxygen intermediates. Br J Dermatol 1982, 107:209-214.
24. Booth S.A., Moody C.E., Dahl M.V., et al. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992, 98:135-140.
25. Wozel G., Lehmann B. Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes. Skin Pharmacol 1995, 8:196-202.
26. Ruzicka T.H., Wassermann S.I., Soter N.A., et al. Inhibition of rat mast cell arachidonic acid cyclooxygenase by dapsone. J Allergy Clin Immunol 1983, 72:365-370.
27. Lehmann B, Wozel G. Inhibition of the prostaglandin endoperoxide H synthases-1 and -2 mediated by TBX2 production by dapsone in human whole blood stimulated ex vivo [abstract]. Presented at: 16th European Workshop on Inflammation. Leipzig, Germany, December 5-8, 1996.
28. Debol S.M., Herron M.J., Nelson R.D. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997, 62:827-836.
29. Theron A., Anderson R. Investigation of the protective effects of the antioxidants ascorbate, cysteine, and dapsone on the phagocyte-mediated oxidative inactivation of human alpha-1-protease inhibitor in vitro. Am Rev Respir Dis 1985, 132:1049-1054.
30. Bonney R.J., Wightman P.D., Dahlgren M.E., et al. Inhibition of the release of prostaglandins, leukotrienes and lysosomal acid hydrolases from macrophages by selective inhibitors of lecithin biosynthesis. Biochem Pharmacol 1983, 32:361-366.
31. 4 binding and bioresponse at the cellular and physiologic level. Eur J Pharmacol 1988, 158:85-89.
32. Blasum CH. Untersuchungen zur Beeinflussung der Interleukin-8-Produnktion in LPS-stimuliertem Vollblut durch dermatlogisch relevante Radikalfänger [thesis]. Dresden, Germany: Department of Dermatology, University Hospital Carl Gustav Carus Dresden; 1996.
33. Beiguelman B., Pisani C.B. Effect of DDS on phytohemagglutinin-induced lymphocyte transformation. Int J Lepr Other Mycobact Dis 1974, 42:412-415.
34. Hamada K., Hiyoshi T., Kobayashi S., et al. Anticonvulsive effect of dapsone (4,4'-diaminodiphenyl sulfone) on amygdale-kindled seizures in rats and cats. Epilepsy Res 1991, 10:93-102.
35. Ishida S., Hamada K., Yagi K. Comparing the anticonvulsive effects of dapsone on amygdale-kindled seizures and hippocampal-kindled seizures in rats. Acta Neurol Scand 1992, 85:132-135.
36. Altagracia M., Monroy-Noyola A., Osorio-Rico L., et al. Dapsone attenuates kainic acid-induced seizures in rats. Neurosci Lett 1994, 176:52-54.
37. Blasum C.H., Lehmann B., Blümlein K., et al. The dapsone metabolite dapsone hydroxylamine is a highly effective anti-inflammatory agent in experimental models of inflammation. Arch Dermatol Res 1998, 290:P34.
38. 4-induced chemotaxis of polymorphonuclear leukocytes into human skin: results of a pilot study. Inflamm Res 1997, 46:420-422.
39. Aschoff R., Wozel G. In vivo modulation of UV-induced erythema by topical dapsone and dapsone metabolites. Skin Pharmacol Appl Skin Physiol 2000, 13:219.
40. Wozel G., Blümlein K., Blasum C., et al. Comments to 'preventive effect of dapsone on renal scarring following mannose-sensitive piliated bacterial infection' by Mochida, et al. (Chemotherapy 1998;44:36-41). Chemotherapy 1999, 45:233-234.
41. Schumacher K. Humane in-vivo-Untersuchungen zur antientzündlichen Wirksamkeit von Diaminodiphenylsulfon (Dapson) [thesis]. Dresden, Germany: Department of Dermatology, University Hospital Carl Gustav Carus Dresden; 1996.
42. Wozel G., Köstler E., Barth J. Ergebnisse von Therapiestudien mit antientzündlichen Substanzen unter Okklusivbedingungen bei Psoriasis. Dermatol Monatsschr 1988, 174:421-423.
43. Harvath L., Yancey K.B., Katz St.I. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones. J Immunol 1986, 137:1305-1311.
44. Pfeiffer C.H., Wozel G. Comments to 'dapsone and sulfones in dermatology: overview and update'. J Am Acad Dermatol 2003, 48:308-309.
45. Cohen D.M., BenAmitai D., Feinmesser M., et al. Childhood lichen planus pemphigoides: a case report and review of the literature. Pediatr Dermatol 2009, 26:569-574.
46. Fredenberg M.F., Malkinson F.D. Sulfone therapy in the treatment of leukocytoclastic vasculitis. J Am Acad Dermatol 1987, 16:772-778.
47. Kardos M., Levine D., Gürcan H.M., et al. Pemphigus vulgaris in pregnancy: analysis of current data on the management and outcomes. Obstet Gynecol Surv 2009, 64:739-749.
48. Nestle F.O., Kaplan D.H., Barker J. Mechanisms of disease: psoriasis. N Engl J Med 2009, 361:496-509.
49. Draelos Z.D., Carter E., Maloney J.M., et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007, 56:439. e1-10.
50. Esterly N.B., Furey N.L., Flanagan L.E. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978, 70:51-55.
51. Millar B.W., Macdonald K.J.S., Macleod T.M., et al. Dapsone and human polymorphonuclear leukocyte chemotaxis in dermatitis herpetiformis. Acta Derm Venereol 1984, 64:433-436.
52. Esca S.A., Pehamberger H., Silny W., et al. Polymorphonuclear leukocyte chemotaxis in dermatitis herpetiformis. Acta Derm Venereol 1981, 61:61-63.
53. Anderson R., Gatner E.M.S., Van Rensburg C.E., et al. In vitro and in vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob Agents Chemother 1981, 19:495-503.
54. Jones R.R. Effect of roaccutane and dapsone on leucotriene B4-induced microabscess formation in vivo. J Invest Dermatol 1985, 84:446.
55. Ruzicka T.H., Bauer A., Glück S., et al. Effect of dapsone on passive Arthus reaction and chemotaxis and phagocytosis of polymorphonuclear leukocytes. Arch Dermatol Forsch 1981, 270:347-351.
56. Bundino S., Zina A.M., Ubertalli S. Infantile acropustulosis. Dermatologica 1982, 165:615-619.
57. Mirochnick M., Cooper E., McIntosh K., et al. Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 1999, 43:2586-2591.
58. Wozel G. The story of sulfones in tropical medicine and dermatology. Int J Dermatol 1989, 28:17-21.
59. Frayling I.M., Addison G.M., Chattergee K., et al. Methaemoglobinaemia in children treated with prilocaine-lignocaine cream. Br Med J 1990, 301:153-154.
60. Grunwald M.H., Amichai B. Dapsone-the treatment of infectious and inflammatory diseases in dermatology. Int J Antimicrob Agents 1996, 7:187-192.
61. Coleman M.D. Dapsone toxicity: some current perspectives. Gen Pharmacol 1995, 26:1461-1467.
62. Rhodes L.E., Tingle M.D., Park B.K., et al. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Br J Dermatol 1995, 132:257-262.
63. Miyagawa S., Shiomi Y., Fukumoto T., et al. Recombinant granulocyte colony-stimulating factor for dapsone-induced agranulocytosis in leukocytoclastic vasculitis. J Am Acad Dermatol 1993, 28:659-661.
64. Stöckel S., Meurer M., Wozel G. Dapsone-induced photodermatitis in a patient with linear IgA dermatosis. Eur J Dermatol 2001, 11:50-53.
65. Homeida M., Babikr A., Daneshmend T.K. Dapsone-induced optic atrophy and motor neuropathy. Br Med J 1980, 281:1180.
66. Kenner D.J., Holt K., Agnello R., et al. Permanent retinal damage following massive dapsone overdose. Br J Ophthalmol 1980, 64:741-744.
67. Zhu K.J., Het F.T., Jin N., et al. Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone-induced hypersensitivity syndrome. J Clin Pharm Ther 2009, 34:489-492.
68. Wozel G., Göbel K. Hypersensitivity syndrome to dapsone-an epidemiological review. Skin and environment-perception and protection. 10th EADV Congress, Munich, 2001 2001, 105-110. Medimond Inc, Bologna (Italy). J. Ring, S. Weidinger, U. Darsow (Eds.).
69. Lorenz M., Wozel G. Hypersensitivity syndrome to dapsone: an epidemiological review and re-evaluation. Basic Clin Pharmacol Toxicol 2009, 104:508-509.